Results 131 to 140 of about 4,719 (152)

Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH)

European Journal of Clinical Pharmacology, 2011
Arginine vasopressin (AVP) is the major physiological regulator of renal water excretion and blood volume. The AVP pathways of V(1a)R-mediated vasoconstriction and V(2)R-induced water retention represent a potentially attractive target of therapy for edematous diseases.
Natig Gassanov, Nasser Semmo, Mariam Semmo   +2 more
exaly   +4 more sources

Effects of an oral vasopressin receptor antagonist (OPC‐31260) in a dog with syndrome of inappropriate secretion of antidiuretic hormone

Australian Veterinary Journal, 2000
ObjectiveThe syndrome of inappropriate secretion of antidiuretic hormone is a rare disorder in dogs characterised by hypo‐osmolality and persistent arginine vasopressin production in the absence of hypovolaemia and/or hypotension. The study describes the efficacy and safety of the nonpeptide selective arginine vasopressin V2receptor antagonist OPC ...
L M Fleeman, Peter J Irwin, P A Phillips
exaly   +5 more sources

Vasopressin V2 receptor antagonists for the syndrome of inappropriate antidiuretic hormone secretion

International Urology and Nephrology, 2023
Masayuki Tanemoto
exaly   +3 more sources

Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide

The American Journal of Medicine, 2001
info:eu-repo/semantics ...
openaire   +3 more sources

Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985

Journal of Laboratory and Clinical Medicine, 2001
VPA-985 is an orally active, competitive vasopressin V(2) receptor antagonist that in normal human beings increases water excretion without affecting solute excretion. Whether solute excretion is affected in patients with hyponatremia resulting from inappropriate secretion of antidiuretic hormone (SIADH) or from cirrhosis treated with VPA-985 is ...
openaire   +3 more sources

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Özge Gumusay, Damé Idossa   +2 more
exaly  

186 Use of tolvaptan, a new V2 receptor antagonist, in the treatment of syndrome of inappropriate antidiuretic hormone secretion (SIADH) secondary to small cell lung cancer (SCLC) – a case series

Lung Cancer, 2014
I.M. Fraser, A.M. Brooke, N.E. Dorey, E.W. Toy   +3 more
openaire   +1 more source

Safety and Efficacy of Vaptans in the Treatment of Hyponatremia from Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH): A Systematic Review and Meta-Analysis

Journal of Clinical Medicine, 2023
Pajaree Krisanapan, Supawit Tangpanithandee, Charat Thongprayoon   +2 more
exaly  

Tolvaptan for Treatment of Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) in a Child with Corpus Callosum Agenesis

Indian Journal of Pediatrics, 2023
Rajni Sharma, Biswaroop Chakrabarty, Sheffali Gulati   +2 more
exaly  

Anomalous antidiuretic activity of antidiuretic hormone antagonists

Biochemical Pharmacology, 1993
Lewis B Kinter, William F Huffman
exaly